WHWK Whitehawk Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1422142 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-72.5%
TTM net income YoY67.7%
TTM EPS YoY86.0%
Revenue 3-yr CAGR-22.3%
Net income 3-yr CAGR—
Margins
Gross margin89.4%
Operating margin-1,601.1%
Net margin-288.3%
FCF margin-1,371.4%
EBITDA margin-1,600.0%
Returns
ROE-21.8%
ROA-18.6%
ROIC (approx.)-147.5%
Asset turnover0.06x
Leverage & solvency
Liabilities / assets9.6%
Debt / equity0.00x
Current ratio10.26x
Interest coverage—
Cash quality & payout
Operating cash flow / net income4.73x
Accruals ratio69.5%
Payout ratio—
Capex / revenue7.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $7.14M | $25.98M |
| Cost of revenue | $760,000 | $3.02M |
| Gross profit | $6.38M | $22.96M |
| R&D expense | $90.96M | $51.03M |
| SG&A expense | $29.82M | $36.75M |
| Operating income | -$114.40M | -$67.46M |
| Interest expense | $0 | $154,000 |
| Pretax income | -$20.60M | -$63.69M |
| Income tax | $0 | $0 |
| Net income | -$20.60M | -$63.69M |
| EBITDA | -$114.32M | -$67.27M |
| EPS (basic) | -0.33 | -2.36 |
| EPS (diluted) | -0.33 | -2.36 |
| Weighted avg. shares (diluted) | 61.89M | 27.03M |
| Balance sheet | ||
| Cash & equivalents | $37.57M | $28.67M |
| Short-term investments | $108.13M | $18.57M |
| Receivables | $0 | $5.90M |
| Inventory | $0 | $5.31M |
| Current assets | $149.01M | $61.29M |
| PP&E, net | $3,000 | $6.85M |
| Total assets | $150.83M | $70.32M |
| Current liabilities | $14.52M | $17.07M |
| Total liabilities | $14.52M | $17.84M |
| Shareholders' equity | $136.31M | $52.48M |
| Shares outstanding | 47.15M | 24.68M |
| Cash flow statement | ||
| Operating cash flow | -$97.43M | -$59.55M |
| Capital expenditure | $552,000 | $1.65M |
| Free cash flow | -$97.98M | -$61.20M |
| Investing cash flow | $11.89M | $25.20M |
| Financing cash flow | $94.38M | $130,000 |
| Depreciation & amortization | $79,000 | $193,000 |
| Stock-based compensation | $9.87M | $10.84M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.